35 results
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
7 May 24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7:09am
in the second half of 2024.
Beam continues to advance and invest in its Engineered Stem Cell Antibody Paired Evasion (ESCAPE) conditioning platform … directed toward reaching each of the key anticipated milestones for BEAM-101, ESCAPE, BEAM-301 and BEAM-302 described above, as well as continued
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
27 Feb 24
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
6:43am
continues to advance and invest in its Engineered Stem Cell Antibody Paired Evasion (ESCAPE) conditioning platform and anticipates initiating Phase 1 … reaching each of the key anticipated milestones for BEAM-101, ESCAPE, BEAM-301 and BEAM-302 described above, as well as continued investments
8-K
EX-99.1
ueumrvx1 boomdg1
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
EX-99.2
12nv54 3u
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
EX-99.1
52p31nx
8 Nov 23
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
dqg82h 56x3
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
EX-99.2
24phnimcxora g6ajjp6
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
pakcl4
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
EX-99.1
s3onmg8rio ybrwfstb
8 Aug 23
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
7:11am
8-K
EX-99.1
s69tn 1g7xh186my
10 May 23
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
qek0oiool4c3pfld
7 Nov 22
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
7:00am